A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, AME Bos, EGE de Vries… - British journal of …, 2001 - nature.com
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
[引用][C] A phase I and pharmacokinetic study of intraperitoneal topotecan
LS HOFSTRA, AME BOS, EGE DE VRIES… - British journal of …, 2001 - pascal-francis.inist.fr
A phase I and pharmacokinetic study of intraperitoneal topotecan CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search …
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search …
[引用][C] A phase I and pharmacokinetic study of intraperitoneal topotecan
L HOFSTRA - Br. J. Cancer, 2001 - cir.nii.ac.jp
A phase I and pharmacokinetic study of intraperitoneal topotecan | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
A phase I and pharmacokinetic study of intraperitoneal topotecan.
LS Hofstra, AME Bos, EGE de Vries… - British Journal of …, 2001 - search.ebscohost.com
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
[PDF][PDF] A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, AME Bos, EGE de Vries… - British Journal of …, 2001 - researchgate.net
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, AM Bos, EG de Vries… - British journal of …, 2001 - pubmed.ncbi.nlm.nih.gov
Purpose To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods Fifteen patients with recurrent ovarian cancer in a phase I trial were …
[PDF][PDF] A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, AME Bos, EGE de Vries… - British Journal of …, 2001 - Citeseer
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, AME Bos, EGE de Vries… - British Journal of …, 2001 - ncbi.nlm.nih.gov
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
A phase I and pharmacokinetic study of intraperitoneal topotecan
LS Hofstra, EGE de Vries, AGJ van der Zee… - British Jounal of …, 2001 - research.rug.nl
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan.
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were …
A phase I and pharmacokinetic study of intraperitoneal topotecan.
LS Hofstra, AM Bos, EG de Vries… - British Journal of …, 2001 - europepmc.org
A phase I and pharmacokinetic study of intraperitoneal topotecan Page 1 Topotecan (Hycamtin),
a semisynthetic water-soluble derivate of camptothecin, is a potent inhibitor of DNA …
a semisynthetic water-soluble derivate of camptothecin, is a potent inhibitor of DNA …